CYP2C19- and CYP3A4-dependent omeprazole metabolism in West Mexicans

被引:42
作者
Gonzalez, HM
Romero, EM
Peregrina, AA
Chávez, TD
Escobar-Islas, E
Lozano, F
Hoyo-Vadillo, C
机构
[1] IPN, CINVESTAV, Div Pharmacol, Mexico City 07360, DF, Mexico
[2] Univ Guadalajara, CUCEI, Guadalajara 44430, Jalisco, Mexico
关键词
omeprazole; CYP2C19; CYP3A4; pharmacogenetics; Mexicans; genetic polymorphisms;
D O I
10.1177/0091270003258170
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Omeprazole has been used as a drug probe for CYP2C19, but no systematic data are available for Mexican populations. The aim of this study was to evaluate the phenotype frequencies of the CYP2C19 polymorphism in West Mexicans. Besides omeprazole, sulfone was measured to evaluate CYP3A4 after administration of the 20-mg dose to 127 healthy volunteers. Logarithms of metabolic indexes of omeprazole/hydroxyomeprazole for CYP2C19 and omeprazole/omeprazole sulfone for CYP3A4 had trimodal distributions. Five subjects (4%) had a log CYP2C19 metabolic index below -0.9, suggesting an ultra-extensive phenotype. Poor metabolizers (log metabolic index > 0.6) were 6%. For GYP3A4, 11 subjects (9%) were below -0.3 of the log metabolic index. The log metabolic index of omeprazole/omeprazole sulfone was above the antimode of 0.6 for 11% of this population. The mean log metabolic index of CYP3A4 extensive metabolizers (80%) was 0.166, which seems to be higher than the data described for Caucasians and lower than that for Asians.
引用
收藏
页码:1211 / 1215
页数:5
相关论文
共 31 条
[11]   Clinical relevance of genetic polymorphisms in the human CYP2C subfamily [J].
Goldstein, JA .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 52 (04) :349-355
[12]   Phenotype of CYP2C19 and CYP3A4 by determination of omeprazole and its two main metabolites in plasma using liquid chromatography with liquid-liquid extraction [J].
González, HM ;
Romero, EM ;
Chavez, TD ;
Peregrina, AA ;
Quezada, V ;
Hoyo-Vadillo, C .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2002, 780 (02) :459-465
[13]   Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype [J].
Herrlin, K ;
Massele, AY ;
Jande, M ;
Alm, C ;
Tybring, G ;
Abdi, YA ;
Wennerholm, A ;
Johansson, I ;
Dahl, ML ;
Bertilsson, L ;
Gustafsson, LL .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 64 (04) :391-401
[14]   OMEPRAZOLE - OVERVIEW AND OPINION [J].
HOLT, S ;
HOWDEN, CW .
DIGESTIVE DISEASES AND SCIENCES, 1991, 36 (04) :385-393
[15]   CLINICAL-PHARMACOLOGY OF OMEPRAZOLE [J].
HOWDEN, CW .
CLINICAL PHARMACOKINETICS, 1991, 20 (01) :38-49
[16]   PHARMACOKINETICS OF NIFEDIPINE SLOW RELEASE TABLET IN MEXICAN SUBJECTS - FURTHER EVIDENCE FOR AN OXIDATION POLYMORPHISM [J].
HOYOVADILLO, C ;
CASTANEDAHERNANDEZ, G ;
HERRERA, JE ;
VIDALGARATE, J ;
MORENORAMOS, A ;
CHAVEZ, F ;
HONG, E .
JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 29 (09) :816-820
[17]  
Karam WG, 1996, DRUG METAB DISPOS, V24, P1081
[18]   Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects [J].
Katsuki, H ;
Nakamura, C ;
Arimori, K ;
Fujiyama, S ;
Nakano, M .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 52 (05) :391-396
[19]  
Kimura M, 2002, CONTACT DERMATITIS, V47, P115
[20]   INTERACTION BETWEEN GRAPEFRUIT JUICE AND MIDAZOLAM IN HUMANS [J].
KUPFERSCHMIDT, HHT ;
HA, HR ;
ZIEGLER, WH ;
MEIER, PJ ;
KRAHENBUHL, S .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 58 (01) :20-28